<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE336nnn/GSE336658/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE336658</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Fibroblast-driven transcriptional reprogramming in response to doxorubicin in heterotypic melanoma spheroids</name><description>Bulk RNA-sequencing was used to compare the transcriptional response to doxorubicin (DOX) between two multicellular melanoma spheroid models: a baseline model composed of B16.F10 melanoma cells, 2H11 endothelial cells, and bone marrow-derived macrophages (BEM), and a fibroblast-containing counterpart (BEMF) additionally incorporating primary murine dermal fibroblasts. Spheroids of each model were exposed for 48 h to their respective IC30 concentration of doxorubicin (0.56 microM for BEM; 0.79 microM for BEMF) or left untreated as controls, in two independent biological replicates per model/treatment combination. RNA-seq was performed to identify differentially expressed genes associated with fibroblast-dependent modulation of the doxorubicin response in melanoma spheroids.</description><dates><publication>2026/06/30</publication></dates><accession>GSE336658</accession><cross_references><GSM>GSM9840071</GSM><GSM>GSM9840072</GSM><GSM>GSM9840070</GSM><GSM>GSM9840068</GSM><GSM>GSM9840069</GSM><GSM>GSM9840066</GSM><GSM>GSM9840067</GSM><GSM>GSM9840073</GSM><GPL>24247</GPL><GSE>336658</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>